Covid - 19 : The increased burden of care and effect on girls’ schooling

Prior to the pandemic, a time-use survey conducted by UN Women confirmed that women are providing the majority of unpaid care and domestic labor in Afghanistan.

Women spent an average of 4.6 hours on childcare compared to 2.3 hours for men; 3.4 hours caring for others compared to 1.3 hours for men; 3.6 hours preparing food compared to 0.4 hours for men; and 7.3 hours on cleaning compared to 1.6 hours for men. In total, women spend an average of 18.7 hours a day on unpaid care and domestic labor compared to 5.6 for men.

As outlined in the Gender Alert 4 on the Impact of COVID-19 on Women’s Burden of Care and Unpaid Domestic Labor,lockdown and social distancing have significantly exacerbated the already high and disproportionate burden of unpaid care and domestic labor responsibilities women and girls experience in Afghanistan.

Forthcoming research by UN Women found that 83% of women saw an increase in unpaid care work and 80% in unpaid domestic work, compared to 75% and 62% for men respectively.Female single parents, including unmarried, widowed and divorced women, felt the burden the most, adding to the other household chores and care work.

Girls are often expected to help shoulder the burden of care and domestic labor in their homes, and as this burden has increased during the pandemic—and school closures have made girls more available to perform this work—it is affecting their future. The increased burden of care is hampering female students’ learning time, resulting in increased learning loss, and affecting their return to schools.

Comments

Increased risks of drop out for women and girls : CoronaVirus Updates

The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime. The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study. These factors combine in harmful ways with pre-existing discriminatory gender norms, o...

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points, the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients . The clinical study evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...

Important information of covid 19 and healthcare tips how to recover from corona virus

Search This Blog